Clever Leaves Holdings Inc. cultivates, extracts, manufactures, and commercializes pharmaceutical-grade cannabinoid products in Colombia, Portugal, Germany, the United States, and Canada.
Share Price & News
How has Clever Leaves Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CLVR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CLVR's weekly volatility (9%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how CLVR performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CLVR performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is Clever Leaves Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Clever Leaves Holdings Fundamentals Summary
|CLVR fundamental statistics|
Is CLVR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CLVR income statement (TTM)|
|Cost of Revenue||US$5.50m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.19|
|Net Profit Margin||-288.24%|
How did CLVR perform over the long term?See historical performance and comparison
Is Clever Leaves Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CLVR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CLVR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CLVR is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: CLVR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CLVR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CLVR is good value based on its PB Ratio (2.6x) compared to the US Pharmaceuticals industry average (3.2x).
How is Clever Leaves Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLVR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CLVR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CLVR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CLVR's revenue (49% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: CLVR's revenue (49% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CLVR's Return on Equity is forecast to be high in 3 years time
How has Clever Leaves Holdings performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CLVR is currently unprofitable.
Growing Profit Margin: CLVR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CLVR's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CLVR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLVR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: CLVR has a negative Return on Equity (-37.65%), as it is currently unprofitable.
How is Clever Leaves Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: CLVR's short term assets ($77.5M) exceed its short term liabilities ($56.6M).
Long Term Liabilities: CLVR's short term assets ($77.5M) exceed its long term liabilities ($14.4M).
Debt to Equity History and Analysis
Debt Level: CLVR's debt to equity ratio (42.7%) is considered high.
Reducing Debt: Insufficient data to determine if CLVR's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CLVR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CLVR has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 5.9% each year.
What is Clever Leaves Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CLVR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CLVR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CLVR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CLVR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CLVR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kyle Detwiler (38 yo)
Mr. Kyle Detwiler serves as Chief Executive Officer at Clever Leaves Holdings Inc. since December 18, 2020 and also serves as its Chairman of the Board. He serves as Chairman at Ecomedics S.A.S. (formerly...
CEO Compensation Analysis
Compensation vs Market: Kyle's total compensation ($USD191.55K) is below average for companies of similar size in the US market ($USD1.10M).
Compensation vs Earnings: Kyle's compensation has been consistent with company performance over the past year.
Experienced Management: CLVR's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: CLVR's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: CLVR only recently listed within the past 12 months.
Clever Leaves Holdings Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Clever Leaves Holdings Inc.
- Ticker: CLVR
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$225.581m
- Shares outstanding: 26.20m
- Website: https://www.cleverleaves.com
Number of Employees
- Clever Leaves Holdings Inc.
- 489 Fifth Avenue
- 27th Floor
- New York
- New York
- United States
Clever Leaves Holdings Inc. cultivates, extracts, manufactures, and commercializes pharmaceutical-grade cannabinoid products in Colombia, Portugal, Germany, the United States, and Canada. The company opera...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/20 22:40|
|End of Day Share Price||2021/09/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.